Clinical Trial Update: Angioshield First-In-Human Study to Demonstrate the Preliminary Safety and Efficacy [NA]

View source ↗

Summary

Angioshield's first-in-human study for coronary artery disease has completed, reporting preliminary safety and efficacy objectives.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Angioshield

Snippet

Sponsor: Neograft Technologies, Incorporated | Conditions: Coronary Artery Disease | NA | Status: COMPLETED